Navigation Links
DARPA selects Lawrence Livermore to develop world's first neural device to restore memory
Date:7/8/2014

LIVERMORE, Calif. The Department of Defense's Defense Advanced Research Projects Agency (DARPA) awarded Lawrence Livermore National Laboratory (LLNL) up to $2.5 million to develop an implantable neural device with the ability to record and stimulate neurons within the brain to help restore memory, DARPA officials announced this week.

The research builds on the understanding that memory is a process in which neurons in certain regions of the brain encode information, store it and retrieve it. Certain types of illnesses and injuries, including Traumatic Brain Injury (TBI), Alzheimer's disease, and epilepsy, disrupt this process and cause memory loss. TBI, in particular, has affected 270,000 military service members since 2000.

The goal of LLNL's workdriven by LLNL's Neural Technology group and undertaken in collaboration with the University of California, Los Angeles (UCLA) and Medtronicis to develop a device that uses real-time recording and closed-loop stimulation of neural tissues to bridge gaps in the injured brain and restore individuals' ability to form new memories and access previously formed ones.

The research is funded by DARPA's Restoring Active Memory (RAM) program.

Specifically, the Neural Technology group will seek to develop a neuromodulation systema sophisticated electronics system to modulate neuronsthat will investigate areas of the brain associated with memory to understand how new memories are formed. The device will be developed at LLNL's Center for Bioengineering.

"Currently, there is no effective treatment for memory loss resulting from conditions like TBI," said LLNL's project leader Satinderpall Pannu, director of the LLNL's Center for Bioengineering, a unique facility dedicated to fabricating biocompatible neural interfaces. "This is a tremendous opportunity from DARPA to leverage Lawrence Livermore's advanced capabilities to develop cutting-edge medical devices that will change the health care landscape."

LLNL will develop a state-of-the-art miniature, wireless and chronically implantable neural device that will incorporate both single neuron and local field potential recordings into a closed-loop system to implant into TBI patients' brains. The device--implanted into the entorhinal cortex and hippocampus--will allow for stimulation and recording from 64 channels located on a pair of high-density electrode arrays. The entorhinal cortex and hippocampus are regions of the brain associated with memory.

The arrays will connect to an implantable electronics package capable of wireless data and power telemetry. An external electronic system worn around the ear will store digital information associated with memory storage and retrieval and provide power telemetry to the implantable package using a custom RF-coil system.

Designed to last throughout the duration of treatment, the device's electrodes will be integrated with electronics using advanced LLNL integration and 3D packaging technologies. The microelectrodes that are the heart of this device are embedded in a biocompatible, flexible polymer.

Using the Center for Bioengineering's capabilities, Pannu and his team of engineers (neurotech.llnl.gov/people) have achieved 25 patents and many publications during the last decade. The team's goal is to build the new prototype device for clinical testing by 2017.

Lawrence Livermore's collaborators, UCLA and Medtronic, will focus on conducting clinical trials and fabricating parts and components, respectively.

"The RAM program poses a formidable challenge reaching across multiple disciplines from basic brain research to medicine, computing and engineering," Itzhak Fried, lead investigator for the UCLA on this project and a professor of neurosurgery and psychiatry and biobehavioral sciences at the David Geffen School of Medicine at UCLA and the Semel Institute for Neuroscience and Human Behavior. "But at the end of the day, it is the suffering individual, whether an injured member of the armed forces or a patient with Alzheimer's disease, who is at the center of our thoughts and efforts."

LLNL's work on the Restoring Active Memory program supports President Obama's Brain Research through Advancing Innovative Neurotechnologies (BRAIN) initiative.

"Our years of experience developing implantable microdevices, through projects funded by the Department of Energy (DOE), prepared us to respond to DARPA's challenge," said Lawrence Livermore Engineer Kedar Shah, a project leader in the Neural Technology group.


'/>"/>

Contact: Ken Ma
ma28@llnl.gov
925-423-7602
DOE/Lawrence Livermore National Laboratory
Source:Eurekalert  

Related medicine news :

1. Cooper Consulting Partners Selects Launch Agency to Brand New Company
2. Newman Regional Health Selects New Chief Executive Officer
3. UF Health Shands Center Selects BESLER Consulting’s Transfer DRG Revenue Recovery Service
4. HM Insurance Group Selects Array Health for Its Online Marketplace for Supplemental Insurance Products
5. NuScale Power Selects Synergy Business Solutions to Implement Microsoft Dynamics SL Project-accounting and Financial Software
6. University of Kentucky Health System Selects lifeIMAGE for Medical Image Sharing
7. Healthconnect Selects Surescripts to Reduce Medication Errors
8. Mississippi Department of Mental Health Selects CoCENTRIX for EHR and to Coordinate Care for Its Citizens Treated in State Behavioral Health and I/DD Programs
9. San Francisco Health Plan Selects Essette to Provide a Comprehensive Care Management Suite
10. KLN Selects abas-USA as Their ERP Vendor
11. Dr. Irwin Selects Personal Microdermabrasion Device as October Product of the Month on Skintour.com
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
DARPA selects Lawrence Livermore to develop world's first neural device to restore memory
(Date:6/25/2016)... ... 2016 , ... The temporary closing of Bruton Memorial Library on June 21 due to a ... new, often overlooked aspect of head lice: the parasite’s ability to live away from a ... occurrence, but a necessary one in the event that lice have simply gotten out of ...
(Date:6/25/2016)... CA (PRWEB) , ... June 25, 2016 , ... As ... with Magna Cum Laude and his M.D from the David Geffen School of Medicine ... and returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive ...
(Date:6/25/2016)... ... ... Conventional wisdom preaches the benefits of moderation, whether it’s a matter of indulgence ... high can result in disappointment, perhaps even self-loathing. However, those who set the bar ... from PsychTests.com reveals that behind the tendency to set low expectations is ...
(Date:6/24/2016)... ... ... June 19, 2016 is World Sickle Cell Observance Day. In an effort to ... treatments, Serenity Recovery Center of Marne, Michigan, has issued a pain management ... (SCD) is a disorder of the red blood cells, which can cause episodes of ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Global law firm ... 2016 Legal Elite. The attorneys chosen by their peers for this recognition are considered ... Seven Greenberg Traurig Shareholders received special honors as members of this year’s Legal Elite ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016  Arkis BioSciences, a leading innovator ... more durable cerebrospinal fluid treatments, today announced it ... funding is led by Innova Memphis, followed by ... private investors.  Arkis, new financing will accelerate the ... market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... June 23, 2016 Any dentist who has made ... the current process. Many of them do not even offer ... difficulties and high laboratory costs involved. And those who ARE ... at such a high cost that the majority of today,s ... Dr. Parsa Zadeh , founder of Dental Evolutions Inc. ...
(Date:6/23/2016)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that ... PCT (procalcitonin) assay as a dedicated testing solution for ... clearance, Roche is the first IVD company in the ... risk assessment and management. PCT is a ... in blood can aid clinicians in assessing the risk ...
Breaking Medicine Technology: